{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:52:26Z","timestamp":1761630746449,"version":"3.41.2"},"reference-count":12,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:p>Juvenile dermatomyositis (JDM) is the most common form of juvenile idiopathic inflammatory myopathy. We report a child with steroid-dependent JDM refractory to hydroxychloroquine and subcutaneous methotrexate who experienced systemic reactions to intravenous immunoglobulin and was successfully treated with subcutaneous immunoglobulin. This form of therapy has been shown to be safe, has a very low rate of adverse effects, does not require hospital admission, reduces the number of missed school days, and decreases the costs associated with treatment.<\/jats:p>","DOI":"10.1542\/peds.2015-3537","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T14:12:27Z","timestamp":1457619147000},"source":"Crossref","is-referenced-by-count":10,"title":["Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis"],"prefix":"10.1542","volume":"137","author":[{"given":"Jaime","family":"de Inocencio","sequence":"first","affiliation":[{"name":"Section of Pediatric Rheumatology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Enr\u00edquez-Merayo","sequence":"additional","affiliation":[{"name":"Section of Pediatric Rheumatology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Casado","sequence":"additional","affiliation":[{"name":"Section of Pediatric Rheumatology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Ignacio","family":"Gonz\u00e1lez-Granado","sequence":"additional","affiliation":[{"name":"Section of Pediatric Immunodeficiency Diseases, Department of Pediatrics, University Hospital 12 de Octubre, Universidad Complutense de Madrid and Instituto de Investigaci\u00f3n Hospital 12 Octubre, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2016,4,1]]},"reference":[{"issue":"1","key":"2021120921364655100_B1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review.","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2021120921364655100_B2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference.","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2021120921364655100_B3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"journal-title":"Lancet","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial [published online ahead of print November 27, 2015].","author":"Ruperto","key":"2021120921364655100_B4"},{"issue":"9","key":"2021120921364655100_B5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3899\/jrheum.090953","article-title":"Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey.","volume":"37","author":"Stringer","year":"2010","journal-title":"J Rheumatol"},{"issue":"12","key":"2021120921364655100_B6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40265-013-0094-3","article-title":"Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.","volume":"73","author":"Lingman-Framme","year":"2013","journal-title":"Drugs"},{"issue":"6","key":"2021120921364655100_B7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"issue":"1","key":"2021120921364655100_B8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/pai.12026","article-title":"Subcutaneous immunoglobulin: rapid push versus infusion pump in pediatrics.","volume":"24","author":"Shapiro","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"2021120921364655100_B9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s13554-014-0018-0","article-title":"Enhancing patient flexibility of subcutaneous immunoglobulin G dosing: pharmacokinetic outcomes of various maintenance and loading regimens in the treatment of primary immunodeficiency.","volume":"4","author":"Sidhu","year":"2014","journal-title":"Biol Ther"},{"issue":"3","key":"2021120921364655100_B10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application.","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"10","key":"2021120921364655100_B11","first-page":"646","article-title":"Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications.","volume":"16","author":"Gelardi","year":"2014","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"2021120921364655100_B12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1756285614563056","article-title":"Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.","volume":"8","author":"Hadden","year":"2015","journal-title":"Ther Adv Neurol Disorder"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3537\/1094570\/peds_20153537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3537\/1094570\/peds_20153537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T22:51:41Z","timestamp":1718405501000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/137\/4\/e20153537\/81485\/Subcutaneous-Immunoglobulin-in-Refractory-Juvenile"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,1]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,1]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-3537","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2016,4,1]]},"article-number":"e20153537"}}